h
ypercytokinemia
hallmark
cytokin
releas
syndrom
excess
uncontrol
releas
proinflammatori
mediat
result
overwhelm
system
inflamm
multipl
organ
failur
left
uncontrol
lead
death
origin
describ
graftversushost
diseas
hypercytokinemia
recent
identifi
fundament
characterist
immunopatholog
varieti
infecti
diseas
includ
primari
influenza
ebola
viru
diseas
malaria
virusassoci
hemophagocyt
lymphohistiocytosi
hlh
hypercytokinemia
also
observ
sepsi
primari
p
secondari
hlh
independ
diseas
trigger
diseas
share
clinic
laboratori
manifest
includ
fever
malais
organomegali
leukopenia
thrombocytopenia
hyperferritinemia
hypercytokinemia
commonli
refer
cytokin
storm
often
consequ
infecti
trigger
present
exagger
activ
innat
immun
system
tolllik
receptor
tlr
class
protein
serv
trigger
innat
immun
respons
numer
pathogen
consid
key
instig
lead
hypercytokinemia
signal
exampl
thought
import
hypercytokinemia
seen
gramneg
bacteriainduc
sepsi
mice
repeat
stimul
receptor
unmethyl
cpg
dna
numer
bacteria
virus
lead
cytokin
storm
trigger
clinic
laboratori
featur
resembl
hlh
secondari
infect
cytokin
interferon
g
ifng
tumor
necrosi
factor
tnfa
b
extens
studi
context
clinic
hypercytokinemia
ifng
consid
domin
cytokin
afford
biolog
effect
potenti
cell
virtu
ubiquit
express
cognat
receptor
produc
cell
innat
adapt
immun
system
includ
natur
killer
nk
cell
natur
killer
cell
cell
neutrophil
dendrit
cell
ifng
well
place
serv
instig
mediat
cytokin
releas
syndrom
inde
substanti
elev
level
ifng
measur
patient
sever
acut
respiratori
syndrom
hlh
cytokin
driven
diseas
furthermor
overexpress
ifng
transgen
mice
suffici
drive
system
organ
inflamm
anim
model
phlh
shlh
cytokin
neutral
studi
reveal
pivot
role
ifng
model
cytokin
releas
syndrom
ifng
shown
critic
develop
featur
shlh
includ
cytopenia
hepat
dysfunct
although
find
intrigu
relev
pathophysiolog
human
diseas
remain
proven
studi
object
dissect
role
ifng
use
mous
model
shlh
translat
find
correl
ifng
signatur
diseas
paramet
patient
use
model
mimic
infectiondriven
shlh
give
mice
repeat
inject
cpgodn
first
time
quantifi
magnitud
ifng
produc
compar
steadyst
condit
neutral
variou
point
diseas
demonstr
complet
neutral
ifng
activ
organ
necessari
revers
diseas
paramet
abrog
ifng
correl
decreas
ifng
signatur
chemokin
blood
serv
robust
serum
biomark
reflect
diseas
statu
level
posit
correl
shlh
paramet
includ
thrombocytopenia
hyperferritinemia
lymphopenia
result
fact
also
clinic
meaning
could
translat
human
use
data
obtain
pediatr
shlh
patient
children
circul
concentr
found
proport
ifng
level
correl
activ
shlh
paramet
ie
neutropenia
thrombocytopenia
hyperferritinemia
hepat
dysfunct
taken
togeth
result
translat
studi
support
expans
clinic
trial
beyond
blockad
ifng
phlh
cytokin
releas
syndrom
furthermor
observ
support
use
marker
type
ii
interferonopathi
well
indic
respons
therapeut
intervent
buatoi
v
et
al
mous
model
show
interferon
g
ifng
central
immun
pathogenesi
hemophagocyt
lymphohistiocytosi
hlh
ubiquit
express
ifng
receptor
howev
result
cytokin
act
local
tissu
make
spillov
blood
detect
challeng
identifi
ifng
signatur
biomark
blood
reflect
diseas
organ
therefor
pivot
use
mous
model
mimick
infectiondriven
hlh
identifi
ifngdriven
chemokin
blood
biomark
ifng
activ
tissu
level
chemokin
correl
diseas
paramet
mice
importantli
diseas
paramet
sever
pediatr
patient
secondari
hlh
cpgodninject
mice
display
strike
elev
inflammatori
mediat
serum
tissu
mice
n
per
time
point
inject
mg
cpgodn
day
gray
fill
triangl
serum
level
ifng
tnfa
measur
multiplex
assay
use
luminex
technolog
b
quantif
liver
deriv
mrna
obtain
qpcr
day
cpgodn
administ
sampl
collect
hour
inject
valu
mean
standard
error
mean
data
repres
experi
au
arbitrari
unit
ifng
interferon
g
interleukin
tnfa
tumor
necrosi
factor
mrna
messeng
rna
qpcr
quantit
pcr
mice
femal
mice
week
purchas
charl
river
laboratori
larbresl
franc
experi
perform
accord
swiss
veterinari
offic
anim
experiment
patient
serum
sampl
collect
patient
shlh
age
onset
year
interquartil
rang
iqr
year
femal
seen
ospedal
pediatrico
bambino
ge
u
itali
patient
met
diagnost
guidelin
patient
met
patient
met
criteria
note
level
uml
avail
test
perform
routin
institut
patient
recruit
primari
hlh
exclud
base
absenc
famili
histori
absenc
mutat
gene
known
caus
hlh
presenc
normal
function
studi
includ
nk
activ
perforin
express
degranul
assay
underli
infect
demonstr
patient
ebsteinbarr
viru
cytomegaloviru
rotaviru
human
herp
viru
propionibacteria
sepsi
morganella
morganii
osteomyel
serum
sampl
obtain
activ
diseas
present
n
inject
mg
cpgodn
day
gray
fill
triangl
bodi
spleen
weight
monitor
blood
paramet
includ
lymphocyt
platelet
red
blood
cell
count
measur
use
hemavet
analyz
ferritin
serum
concentr
measur
elisa
day
cpgodn
administ
sampl
collect
hour
inject
valu
mean
standard
error
mean
data
repres
experi
statist
perform
indic
time
point
baselin
ie
day
valu
p
p
p
obtain
use
nonparametr
mannwhitney
u
test
shlh
secondari
hemophagocyt
lymphohistiocytosi
patient
multipl
sampl
avail
patient
use
analysi
correl
laboratori
featur
includ
neutrophil
platelet
blood
count
level
ferritin
alanin
transaminas
lactat
dehydrogenas
time
sampl
collect
databas
studi
approv
institut
ethic
committe
inform
consent
obtain
parent
patient
appropri
shlh
mice
shlh
induc
previous
describ
brief
femal
mice
inject
intraperiton
day
mg
cpgodn
invivogen
indic
time
point
mice
euthan
co
inhal
bodi
spleen
weight
record
peripher
blood
collect
microtain
bd
tube
contain
edta
anticoagul
becton
dickinson
complet
blood
count
perform
hemavet
analyz
hematolog
analyz
drew
scientif
antibodi
vivo
use
antimous
ifng
mifng
neutral
mab
rat
isotypematch
control
mab
produc
purifi
novimmun
hybridoma
cultur
supernat
purchas
bioxcel
antibodi
inject
intraven
dose
mgkg
measur
serum
cytokin
chemokin
ferritin
level
mous
human
cytokin
chemokin
level
determin
use
milliplex
map
multiplex
immunodetect
kit
millipor
analyz
luminex
instrument
ferritin
concentr
determin
use
enzymelink
immunosorb
assay
elisa
kit
alpco
diagnost
follow
manufactur
instruct
measur
total
mifng
elisabas
assay
develop
adapt
method
describ
finkelman
morri
allow
quantif
total
ifng
free
bound
differ
ifng
ratio
present
serum
sampl
found
variou
time
point
significantli
affect
assay
perform
thu
procedur
modif
requir
compens
variabl
includ
addit
excess
mgml
sampl
ex
vivo
step
ensur
stabil
mabcytokin
complex
allow
precis
quantif
total
ifng
briefli
maxisorp
plate
nunc
coat
antimifng
mab
mgml
bd
bioscienc
serum
sampl
ad
well
mifng
detect
use
biotinconjug
antimifng
mab
ngml
bd
bioscienc
peroxidasestreptavidin
jacksonimmunoresearch
tetramethylbenzidin
substrat
sigmaaldrich
optic
densiti
read
nm
use
epoch
micropl
reader
biotek
data
analyz
softwar
gene
express
total
rna
spleen
liver
extract
rneasi
mini
kit
qiagen
accord
manufactur
instruct
revers
transcript
perform
use
high
capac
cdna
revers
transcript
kit
appli
biosystem
quantit
pcr
qpcr
perform
triplic
use
sybr
green
master
mix
appli
biosystem
primer
sequenc
gener
use
primer
express
softwar
version
appli
biosystem
sequenc
primer
bactin
forward
agccttccttcttgggtatgg
revers
caa
cgtcacacttcatgatg
gaat
ifng
forward
caacagcaaggcgaa
aaa
gg
revers
cctgtgggttgttga
cctcaa
forward
tgcacgatgctcctgca
revers
aggtct
ttgagggattt
gtagtgg
forward
gacggtccgctgcaactg
revers
gctt
ccctatgg
ccctcatt
mhcii
transactiv
ciita
form
piv
forward
catgcaggcagcact
cagaa
revers
atccat
ggtggcacaca
gact
forward
tcggaggcttaattacac
atgttc
revers
tgccattgcacaactc
ttttct
tnfa
forward
gccaccacg
ctcttctgtct
revers
ggtctgggccata
gaactgatg
rel
express
level
calcul
ct
bactin
bactin
rna
endogen
control
line
day
black
fill
triangl
liver
obtain
evalu
ciita
piv
mrna
ifnginduc
gene
qpcr
b
tnfa
serum
concentr
quantifi
multiplex
assay
use
luminex
technolog
c
quantif
tissuederiv
cytokin
mrna
evalu
qpcr
liver
spleen
e
sampl
day
collect
cpgodn
inject
wherea
sampl
day
day
collect
hour
cpgodn
inject
sampl
day
mab
administr
collect
inject
valu
mean
sem
data
repres
experi
statist
perform
compar
valu
time
point
isotyp
control
treat
group
p
p
p
obtain
use
nonparametr
mannwhitney
u
test
ifng
interferon
g
interleukin
tnfa
tumor
necrosi
factor
mrna
messeng
rna
qpcr
quantit
pcr
histolog
liver
fix
overnight
neutral
buffer
formalin
sigmaaldrich
rins
phosphatebuff
salin
dehydr
embed
paraffin
leica
microsystem
section
stain
hemalun
eosin
vwr
analyz
cell
infiltr
calcul
area
contain
foci
leucocyt
infiltr
use
imagej
softwar
nih
statist
analysi
graphpad
prism
use
statist
analysi
nonparametr
mannwhitney
u
test
use
statist
comparison
group
data
express
mean
standard
error
mean
statist
test
indic
figur
legend
p
valu
consid
signific
indic
statist
analysi
perform
use
spearman
test
ifng
level
track
togeth
accompani
deterior
present
laboratori
clinic
featur
shlh
mice
increas
circul
cytokin
describ
shlh
model
strengthen
data
conduct
experi
follow
kinet
ifng
ifngdepend
chemokin
blood
tissu
stimul
provok
dna
rich
cpgodn
motif
repeatedli
inject
led
hypercytokinemia
fig
within
hour
first
stimul
ifng
tnfa
elev
blood
accompani
de
novo
messeng
rna
mrna
synthesi
proinflammatori
mediat
liver
fig
spleen
supplementari
fig
subsequ
stimul
ifng
level
oscil
similarli
suggest
chemokin
may
biomark
fluctuat
ifng
activ
convers
tnfa
level
measur
stabl
rate
fig
develop
hypercytokinemia
lead
weight
loss
alter
hematolog
paramet
within
hour
first
cpgodn
inject
mice
lost
signific
amount
start
weight
fig
lymphocyt
count
blood
also
decreas
rapidli
remain
low
throughout
studi
fig
repeat
stimul
platelet
erythrocyt
count
steadili
decreas
wherea
splenomegali
increasingli
evid
fig
interestingli
serum
ferritin
marker
inflammatori
respons
spike
day
cpgodn
inject
fig
correl
observ
maxim
level
achiev
blood
inflammatori
mediat
studi
fig
taken
togeth
observ
repeat
stimul
cpgodn
mice
recreat
hypercytokinemia
albeit
peak
trough
manifest
steadi
deterior
laboratori
clinic
paramet
ifng
product
tissu
compart
correl
hypercytokinemia
owe
detail
studi
blood
cytokin
reveal
dynam
fluctuat
ifng
blood
diseas
progress
sustain
hypothes
ifng
may
produc
consum
tissu
wherea
fluctuat
serum
level
repres
spillov
cytokin
blood
investig
possibl
set
quantifi
amount
ifng
produc
tissu
inject
antimifng
mab
mice
receiv
diseas
induc
cpgodn
took
advantag
previous
describ
phenomena
ifng
tissu
captur
drain
via
lymphat
blood
lead
accumul
cytokin
complex
mab
thu
cytokinemab
complex
measur
ex
vivo
blood
sampl
thu
directli
proport
total
amount
ifng
produc
organ
administr
first
cpgodn
inject
result
ifng
measur
ng
ml
serum
reflect
basal
level
product
naiv
mice
fig
cpgodn
inject
mark
increas
total
ifng
reach
ngml
fig
measur
mice
compar
level
measur
without
cytokinemab
complex
stabil
ngml
fig
peak
level
total
ifng
reach
ngml
fig
increas
basal
total
ifng
level
naiv
mice
increas
level
detect
serum
cpgodn
treat
mice
without
fig
demonstr
consider
product
ifng
tissu
mice
undergo
hypercytokinemia
owe
level
total
ifng
produc
model
experi
ifnginduc
diseas
model
exampl
phlh
next
evalu
dose
mgkg
mous
graph
repres
quantit
analysi
least
field
per
liver
captur
fold
increas
area
compar
untreat
mice
ie
cpg
inject
symbol
repres
individu
mous
horizont
line
repres
mean
valu
p
p
p
obtain
use
nonparametr
mannwhitney
u
test
ifng
interferon
g
shlh
secondari
hemophagocyt
lymphohistiocytosi
end
mice
inject
hour
post
cpgodn
administr
mrna
express
liver
ifngdepend
gene
ciita
piv
evalu
time
robust
induct
ciita
piv
mrna
observ
first
cpgodn
inject
elimin
ciita
piv
express
administr
demonstr
complet
neutral
ifng
tissu
achiev
fig
tissuederiv
ifng
respons
clinic
laboratori
featur
cytokin
releas
syndrom
made
novel
observ
high
level
ifng
origin
tissu
stimul
perform
kinet
studi
determin
degre
cytokin
associ
featur
shlh
throughout
durat
model
administ
day
post
peak
total
ifng
mice
challeng
cpgodn
serum
level
tnfa
significantli
lower
maintain
close
baselin
fig
interestingli
neutral
ifng
tissu
result
decreas
mrna
level
liver
fig
spleen
fig
tnfa
liver
fig
ifng
neutral
significantli
reduc
bodi
weight
loss
splenomegali
lymphopenia
thrombocytopenia
anemia
hyperferritinemia
fig
liver
inflamm
illustr
cellular
infiltr
creat
inflammatori
cell
foci
also
reduc
administr
fig
role
ifng
later
stage
diseas
also
investig
clinic
featur
laboratori
abnorm
establish
fig
total
ifng
product
plateau
fig
neutral
ifng
result
abrog
hyperreleas
tnfa
blood
fig
moreov
delay
ifng
neutral
result
reduct
bodi
weight
loss
improv
splenomegali
fig
thrombocytopenia
anemia
hyperferritinemia
amelior
although
lymphopenia
remain
unchang
fig
delay
inhibit
also
control
liver
inflamm
signific
drop
cellular
infiltr
welldecreas
tnfa
mrna
express
observ
fig
taken
togeth
effici
neutral
high
rate
tissu
product
ifng
requir
induc
signific
amelior
cytokin
releas
syndrom
paramet
blood
tissu
level
associ
ifng
activ
cytokin
releas
syndrom
support
hypothesi
chemokin
mirror
ifng
activ
demonstr
ifng
neutral
start
either
diseas
onset
result
signific
decreas
liver
mrna
level
level
fig
signific
decreas
blood
fig
testament
shutdown
chemokin
product
tissu
result
suggest
serum
level
reflect
ifng
activ
shlh
confirm
associ
signific
correl
serum
ifng
level
serum
concentr
observ
cpgtreat
mice
absenc
fig
final
correl
analysi
perform
demonstr
level
ifngdepend
chemokin
blood
associ
syndrom
paramet
includ
thrombocytopenia
hyperferritinemia
lymphopenia
fig
howev
signific
correl
seen
serum
ifng
previous
paramet
except
lymphocyt
count
p
fig
data
reinforc
circul
level
mirror
tissu
ifng
activ
importantli
diseas
paramet
blood
mab
dot
line
isotyp
control
mab
solid
line
day
black
fill
triangl
tnfa
serum
concentr
quantifi
multiplex
assay
use
luminex
technolog
bodi
spleen
weight
monitor
blood
paramet
includ
lymphocyt
platelet
red
blood
cell
count
measur
use
hemavet
analyz
serum
ferritin
measur
elisa
b
liver
inflamm
evalu
day
calcul
area
contain
foci
leukocyt
infiltr
illustr
b
graph
repres
quantit
analysi
least
field
per
liver
captur
fold
increas
area
compar
untreat
mice
ie
cpg
inject
symbol
repres
individu
mous
horizont
line
repres
mean
valu
tnfa
mrna
level
evalu
qpcr
liver
sampl
day
collect
cpgodn
inject
wherea
sampl
day
day
collect
hour
cpgodn
inject
sampl
day
mab
administr
collect
inject
valu
mean
standard
error
mean
data
repres
experi
statist
perform
time
point
isotyp
control
group
p
p
p
obtain
use
nonparametr
mannwhitney
u
test
au
arbitrari
unit
interleukin
tnfa
tumor
necrosi
factor
mrna
messeng
rna
qpcr
quantit
pcr
shlh
secondari
hemophagocyt
lymphohistiocytosi
tabl
blood
level
ifng
median
pgml
iqr
pgml
iqr
pgml
iqr
markedli
higher
patient
sampl
nonact
diseas
follow
effect
treatment
ifng
pgml
iqr
pgml
iqr
pgml
iqr
fig
blood
sampl
obtain
differ
time
activ
shlh
diseas
ifng
level
significantli
correl
level
lesser
extent
fig
also
investig
correl
circul
level
ifng
laboratori
paramet
shlh
includ
neutrophil
platelet
count
ferritin
lactat
dehydrogenas
alanin
transaminas
level
found
blood
level
significantli
correl
laboratori
paramet
studi
fig
ifng
level
also
significantli
correl
previous
mention
diseas
paramet
except
ifng
platelet
count
fig
ferritin
level
fig
reach
signific
taken
togeth
find
patient
suggest
pathogen
role
ifng
shlh
advoc
use
blood
level
potenti
biomark
ifng
activ
shlh
hlh
present
sever
system
inflamm
accompani
hypercytokinemia
potenti
fatal
hyperreleas
inflammatori
mediat
includ
cytokin
chemokin
accur
measur
relat
compon
hypercytokinemia
blood
clinic
laboratori
manifest
diseas
complic
due
chang
cytokin
signatur
time
short
halflif
protein
vivo
determin
accur
level
cytokin
chemokin
patient
hlh
particular
import
investig
link
pathophysiolog
data
also
contribut
understand
potenti
relev
neutral
therapeut
target
thu
use
mous
model
mimick
infectiondriven
shlh
associ
cytokin
releas
syndrom
well
assess
serum
sampl
patient
defin
bloodborn
inflammatori
mediat
hypercytokinemia
caus
diseas
tissu
analys
afford
kinet
studi
perform
anim
model
shlh
demonstr
strong
associ
level
ifng
blood
follow
cpgodn
inject
howev
highaffin
receptor
ifng
ubiquit
express
facilit
rapid
elimin
cytokin
site
product
hypothes
measur
concentr
ifng
blood
poor
indic
true
quantiti
produc
inde
result
support
notion
measur
blood
consid
spillov
event
occur
tissu
succumb
hyperinflamm
adapt
method
exploit
abil
antimous
ifng
mab
captur
ifng
present
organ
mobil
immun
complex
blood
compart
observ
rapid
dramat
increas
ifng
basal
level
first
cpgodn
inject
subsequ
stimul
result
increment
increas
total
ifng
level
final
reach
steadyst
concentr
higher
measur
mice
homeostat
condit
isotyp
control
mab
solid
line
day
b
upper
panel
black
fill
triangl
day
b
lower
panel
black
fill
triangl
mrna
quantif
cytokin
liver
obtain
qpcr
serum
concentr
quantifi
multiplex
assay
use
luminex
technolog
sampl
day
collect
cpgodn
inject
wherea
sampl
day
day
collect
hour
cpgodn
inject
sampl
day
mab
inject
collect
inject
valu
mean
standard
error
mean
data
repres
experi
statist
perform
compar
valu
time
point
isotyp
control
group
p
p
p
p
obtain
use
nonparametr
mannwhitney
u
test
c
mice
inject
mg
cpgodn
day
serum
level
ifng
quantifi
multiplex
assay
use
luminex
technolog
correl
perform
ifng
ifng
level
differ
time
point
hlh
develop
depict
fig
statist
perform
p
valu
obtain
use
spearman
test
line
best
fit
gener
use
nonlinear
regress
analysi
use
grappad
prism
softwar
ifng
interferon
g
mrna
messeng
rna
qpcr
quantit
pcr
shlh
secondari
hemophagocyt
lymphohistiocytosi
tolllik
receptor
importantli
abil
infiltr
organ
demonstr
abrog
tissu
ciita
pivexpress
ifnginduc
gene
diminish
de
novo
transcript
liver
correspond
rapid
disappear
ifnginduc
chemokin
blood
alter
protein
regul
ifng
reinforc
notion
sourc
hypercytokinemia
observ
shlh
occur
organ
level
addit
result
infer
cytokin
level
detect
blood
may
fail
reflect
true
magnitud
total
cytokin
product
occur
bodi
phenomenon
also
exemplifi
sever
infect
affect
respiratori
tract
eg
avian
influenza
sever
primari
influenza
viru
infect
inflammatori
cascad
lead
hypercytokinemia
consequ
immunopatholog
occur
deep
tissu
previous
behren
et
al
nice
demonstr
neutral
ifng
amelior
hlhlike
featur
induc
repeat
cpg
inject
given
balbc
mice
howev
author
conclud
diseas
paramet
leukopenia
hyperferritinemia
ifngindepend
demonstr
neutral
ifng
organ
control
hypercytokinemia
amelior
laboratori
clinic
shlh
paramet
mous
model
circul
level
correl
diseas
paramet
model
shlh
mice
inject
mg
cpgodn
day
serum
level
ifng
quantifi
multiplex
assay
use
luminex
technolog
blood
paramet
includ
platelet
lymphocyt
count
measur
use
hemavet
analyz
serum
ferritin
measur
elisa
correl
perform
diseas
paramet
diseas
paramet
ifng
diseas
paramet
differ
time
point
hlh
develop
depict
fig
statist
perform
p
valu
obtain
use
spearman
test
p
p
p
line
best
fit
gener
use
nonlinear
regress
analysi
use
grappad
prism
softwar
tolllik
receptor
shlh
secondari
hemophagocyt
lymphohistiocytosi
ifng
interferon
g
data
help
explain
observ
lower
dose
ie
mgkg
administ
altern
hlh
model
involv
perforindefici
mice
infect
mous
cytomegaloviru
possibl
significantli
alter
diseas
taken
togeth
result
underlin
local
hyperproduct
ifng
drive
organ
patholog
trigger
inflamm
tissu
damag
ultim
dissemin
system
other
shown
serum
peak
ifng
cpg
inject
although
modest
suggest
import
role
cytokin
drive
tissu
patholog
seen
cpgtreat
mice
nonetheless
use
ifng
blood
biomark
complic
fact
cytokin
rapidli
catabol
use
tissu
limit
address
studi
demonstr
blood
level
chemokin
directli
induc
ifng
alter
correl
hlh
paramet
includ
thrombocytopenia
hyperferritinemia
lymphopenia
abundantli
produc
chemokin
serv
biomark
ifng
activ
mous
organ
clinic
import
find
born
translat
observ
pediatr
patient
shlh
high
level
ifng
detect
blood
patient
activ
diseas
although
infect
demonstr
half
patient
well
known
infecti
trigger
may
alway
appar
time
hlh
diagnosi
moreov
sinc
patient
studi
mutat
known
gene
caus
hlh
normal
degranul
well
perforin
express
nk
cytotox
experi
hlh
reactiv
neg
famili
histori
highli
unlik
patient
phlh
includ
analysi
find
shlh
patient
activ
diseas
high
circul
level
ifng
extend
data
report
xu
et
al
although
report
level
ifng
specif
patient
shlh
found
high
level
ifng
popul
hlh
patient
compris
relev
portion
ie
document
infect
moreov
data
show
level
lesser
extent
blood
correl
measur
ifng
mous
model
shlh
increas
level
correl
sever
laboratori
paramet
diseas
sever
target
ifng
treatment
option
cytokin
releas
syndrom
first
propos
year
ago
number
studi
includ
demonstr
pivot
role
ifng
model
phlh
demonstr
high
rate
ifng
product
tissu
central
syndrom
mice
blood
level
correl
diseas
paramet
anim
model
well
shlh
patient
although
ifng
level
monitor
patient
shlh
observ
support
cytokin
key
driver
hypercytokenimia
hlh
advoc
use
level
biomark
ifng
activ
therefor
anticip
ongo
effort
investig
blockad
ifng
patient
phlh
ultim
support
strategi
therapeut
approach
secondari
form
diseas
author
contribut
follow
v
buatoi
w
ferlin
design
coordin
project
analyz
data
wrote
manuscript
l
chatel
l
con
perform
murin
experi
f
richard
f
guilhot
perform
multiplex
human
sampl
test
c
bracaglia
f
debenedetti
record
gener
databas
human
data
lori
provid
technic
advic
v
buatoi
l
chatel
prepar
figur
manuscript
v
buatoi
w
ferlin
obtain
use
mannwhitney
u
test
b
correl
perform
ifng
level
sera
patient
activ
fullblown
shlh
statist
perform
p
valu
obtain
use
spearman
test
ce
correl
perform
serum
ifng
c
e
level
neutrophil
count
platelet
count
ferritin
ldh
alt
concentr
statist
perform
p
valu
obtain
use
spearman
test
p
p
p
p
line
best
fit
gener
use
nonlinear
regress
analysi
use
grappad
prism
softwar
ifng
interferon
g
shlh
secondari
hemophagocyt
lymphohistiocytosi
alt
alanin
transaminas
ldh
lactat
dehydrogenas
